Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This study is a single arm phase II trial including 30 patients with III-IVB (according to
the 8th edition of UICC/AJCC staging) locally advanced head and neck squamous cell carcinoma
(HNSCC) eligible for resection, who receive Adebrelimab plus Dalpiciclib as neoadjuvant
regimen before surgery.
This proposed study will evaluate the efficacy and safety of preoperative administration of
Adebrelimab plus Dalpiciclib in HNSCC who are eligible for resection.